GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Suzhou Zelgen Biopharmaceuticals Co Ltd (SHSE:688266) » Definitions » Additional Paid-In Capital

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Additional Paid-In Capital : ¥0.0 Mil(As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Suzhou Zelgen Biopharmaceuticals Co Additional Paid-In Capital?


Suzhou Zelgen Biopharmaceuticals Co's quarterly additional paid-in capital increased from Sep. 2023 (¥0.0 Mil) to Dec. 2023 (¥3,279.0 Mil) but then stayed the same from Dec. 2023 (¥3,279.0 Mil) to Mar. 2024 (¥0.0 Mil).

Suzhou Zelgen Biopharmaceuticals Co's annual additional paid-in capital declined from Dec. 2021 (¥2,121.1 Mil) to Dec. 2022 (¥2,101.1 Mil) but then increased from Dec. 2022 (¥2,101.1 Mil) to Dec. 2023 (¥3,279.0 Mil).


Suzhou Zelgen Biopharmaceuticals Co Additional Paid-In Capital Historical Data

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Zelgen Biopharmaceuticals Co Additional Paid-In Capital Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 264.18 2,121.10 2,121.10 2,101.11 3,279.00

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 3,277.27 - 3,279.00 -

Suzhou Zelgen Biopharmaceuticals Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Suzhou Zelgen Biopharmaceuticals Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Suzhou Zelgen Biopharmaceuticals Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Business Description

Traded in Other Exchanges
N/A
Address
No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
Executives
Zhang Bin Core technical personnel
Huang Gang senior management
Lv Bin Hua Directors, senior managers, core technical personn
Lu Hui Ping Directors, senior managers
Gao Qing Ping senior management
Wu Ji Sheng Directors, senior managers, core technical personn
Zhang Jun Li senior management
Wu Li Qing Core technical personnel
Core technical personnel
Sheng Ze Lin Directors, senior managers, core technical personn

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Headlines

No Headlines